Exploring the research gap of patient perspectives

My guest for this episode is Professor Richard Gale, Professor of Ophthalmology at Hull York Medical School, University of York, UK, and Honorary Consultant Medical Ophthalmologist at the National Health Service’s York Teaching Hospital. In this episode, Richard and I will chat about how patients’ emotions, experiences, and perceptions related to anti-vascular endothelial growth factor (anti-VEGF) treatment can influence their treatment adherence and persistence. Despite this, the patient’s perspective is often not considered during the clinical management of neovascular age-related macular degeneration. To tackle this issue, Richard gives us some of his top tips to try in our busy clinics.We discuss a systematic literature review article recently published in Acta Ophthalmologica, which was authored by a group of international experts including Richard and myself. Find out more here: https://doi.org/10.1111/aos.15201If you enjoyed this episode, go back and listen to our first episode with Richard, where we chat about how to further motivate our patients to be adherent, or try some of the past episodes to hear other retinal experts delve into ways to engage and empower our patients, and explore a history of patient expectations in nAMD through the 21st century.SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/  Further information on other studies mentioned in this episode: ANCHOR study: https://doi.org/10.1016/j.ophtha.2008.10.018 MARINA study: https://doi.org/10.1016/j.ophtha.2006.10.045 Prevalence and risk factors for depressive symptoms in patients with nAMD; Australian study: https://doi.org/10.1111/aos.14635This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.This is not intended for UK audiences.Speaker disclosures:Professor Anat LoewensteinConsultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane Professor Richard Gale:Consultancy, Research GraThis podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.